PolyPeptide Group

Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Expand Peptide Therapeutics

South Korea's Samsung Biologics made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group. This acquisition, the largest biopharma M&A in South Korea's history, aims to diversify Samsung's portfolio into fast-growing peptide therapeutics, including obesity treatments, and expand its global footprint.